Role of 5-ht7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat

British Journal of Pharmacology
J A Terrón

Abstract

1. The receptor mediating the long-lasting hypotensive effect of intravenous (i.v.) 5-hydroxytryptamine (5-HT) in the rat was originally classified as 5-HT1-like. Since some pharmacological properties of this receptor are closely similar to those for the cloned 5-ht7 receptor, the present study investigated the effects of several 5-HT receptor agonists and antagonists showing high affinity for the cloned 5-ht7 receptor in pithed rats with artificially raised blood pressure. 2. I.v. bolus administration of 5-HT, 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine, lisuride and sumatriptan to bilaterally vagotomized pithed rats pretreated with ketanserin (0.18 mumol kg-1, i.v.), the diastolic blood pressure of which had been raised by a continuous i.v. infusion of methoxamine (60-80 nmol kg-1 min-1), produced dose-dependent hypotensive responses; only 5-HT and 5-CT displayed similar maximum effects. In addition to mimicking the hypotensive action of 5-HT with a lower maximum effect, lisuride strongly antagonized the 5-CT-induced hypotensive responses thus suggesting a partial agonist effect. The rank order of hypotensive agonist potency was 5-CT > > 5-HT > or = 5-methoxytryptamine > or = lisuride > > sumatriptan. 3. In experiment...Continue Reading

References

Mar 1, 1992·British Journal of Pharmacology·M J SumnerP P Humphrey
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G McAllisterP Whiting
Jan 15, 1991·Brain Research. Developmental Brain Research·B L RothR D Ciaranello
Feb 1, 1990·British Journal of Pharmacology·M J Sumner, P P Humphrey
Jun 12, 1990·European Journal of Pharmacology·I van WijngaardenW Soudijn
Apr 12, 1989·European Journal of Pharmacology·S J Peroutka, B G McCarthy
Aug 1, 1988·British Journal of Pharmacology·P P HumphreyD Butina
Jan 1, 1988·Journal of Receptor Research·D Hoyer
Jul 30, 1984·Life Sciences·M A TrevethickP P Humphrey
May 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Fozard
Jul 15, 1983·European Journal of Pharmacology·H O KalkmanP A Van Zwieten
Dec 9, 1983·European Journal of Pharmacology·W FeniukA D Watts
May 1, 1995·British Journal of Pharmacology·Z P ToL B Jakeman
May 1, 1995·Pharmacology & Therapeutics·P R Saxena
Mar 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·K KrejcyG Raberger
Mar 1, 1995·Trends in Pharmacological Sciences·G BaxterT Blackburn
Jan 1, 1994·British Journal of Pharmacology·J D GaleP P Humphrey
Jan 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·N AdhamT A Branchek
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M RuatJ C Schwartz
Sep 1, 1953·The American Journal of Physiology·I H PAGE, J W McCUBBIN
Apr 1, 1947·Proceedings of the Society for Experimental Biology and Medicine·R E SHIPLEY, J H TILDEN

❮ Previous
Next ❯

Citations

Jul 13, 1999·British Journal of Pharmacology·J A Terrón, A Falcón-Neri
Mar 13, 2012·Pharmacological Reviews·Stephanie W WattsSusan M Barman
Sep 3, 2014·Vascular Pharmacology·Stephanie W Watts
May 2, 2003·Expert Opinion on Investigational Drugs·Sheila A Doggrell
Apr 9, 2005·Current Eye Research·Koen BousseryJohan Van de Voorde
Aug 31, 2007·European Journal of Pharmacology·José A TerrónEsther Martínez-García
Dec 17, 2014·Journal of Cardiovascular Pharmacology·Carolina Sánchez-MaldonadoJosé A Terrón
May 4, 2010·Cardiovascular Therapeutics·Stephanie W Watts, Robert Patrick Davis
May 28, 2019·Physiological Genomics·Elena Y DemirevaStephanie W Watts
May 28, 2019·Physiological Genomics·Bridget M SeitzStephanie W Watts
Feb 29, 2008·The Journal of Pharmacology and Experimental Therapeutics·Jessica DiazStephanie W Watts
Jan 25, 2020·Pain·Alejandro Labastida-RamírezAntoinette MaassenVanDenBrink
Apr 10, 2015·Clinical and Experimental Pharmacology & Physiology·José-Ángel García-PedrazaAsunción Morán
Feb 19, 2015·Pharmacology Research & Perspectives·Stephanie W WattsJanice M Thompson
Nov 3, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Stephanie W Watts
Jun 20, 2017·American Journal of Physiology. Heart and Circulatory Physiology·Bridget M SeitzStephanie W Watts
Mar 10, 2000·American Journal of Physiology. Heart and Circulatory Physiology·T IshineT J Lee
Apr 16, 2021·Frontiers in Neuroscience·Tri Huu DoanTadachika Koganezawa
Jul 13, 2021·Frontiers in Physiology·Bridget M SeitzGregory D Fink
May 25, 2021·Journal of Cardiovascular Pharmacology·Romina Gonzalez-PonsStephanie W Watts
Jun 27, 2003·Journal of Medicinal Chemistry·Richard A Glennon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here